SE
Seyed Ehtesham Hasnain
About Seyed Ehtesham Hasnain
Data last updated:
Seyed Ehtesham Hasnain has 20 years in corporate governance. Holds Director role. Currently with 5 companies, including Suven Life Sciences Limited and Aditum Life Sciences Private Limited. Formerly with 6 companies, such as Envirozyme Biotech Private Limited and Valetude Primus Healthcare Private Limited. Engaged in General Business, Technology and more. The 2 current companies with reported revenue have a combined latest revenue of ₹39.69 Cr; the largest is Dr.Reddy's Institute Of Life Sciences at ₹22.14 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Dr.Reddy's Institute Of Life Sciences U73100TG2003NPL042023 | Director | 01 Jun 2006 | 2003 | ₹22.14 Cr (FY 2025) | Active |
 Suven Life Sciences Limited L24110TG1989PLC009713 | Director | 30 Apr 2010 | 1989 | ₹17.55 Cr (FY 2025) | Active |
 Ignovision Solutions Private Limited U74999DL2014PTC274337 | Director | 10 Nov 2015 | 2014 | – | Active |
| Aditum Life Sciences Private Limited U24299TG2021PTC150717 | Director | 19 Apr 2021 | 2021 | – | Active |
 Sidsam Profeza Technologies India Private Limited U74110HR2007PTC036832 | Director | 16 Jan 2018 | 2007 | – | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Envirozyme Biotech Private Limited U24290TG2019PTC134161 | Director | 23 Mar 2020 | 2019 | – | Active |
 Valetude Primus Healthcare Private Limited U36100DL2015PTC281389 | Director | 27 Jan 2018 | 2015 | ₹1.30 Cr (FY 2020) | Active |
 Indian Immunologicals Limited U72200TG1999PLC032666 | Director | 30 Sep 2010 | 1999 | ₹1,513 Cr (FY 2025) | Active |
 Yashraj Biotechnology Limited U73100MH1999PLC119769 | Additional Director | 04 Oct 2017 | 1999 | ₹88.45 Cr (FY 2025) | Active |
 University Of Hyderabad Knowledge And Innovation Park Private Limited U74900AP2008PTC060473 | Director | 05 Aug 2008 | 2008 | – | Strike Off |
 Ikp Knowledge Park U92190TG1998NPL029821 | Additional Director | 26 Mar 2009 | 1998 | ₹73.90 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Seyed Ehtesham Hasnain
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seyed Ehtesham Hasnain
Seyed Ehtesham Hasnain has 20 years in corporate governance. Holds Director role. Currently with 5 companies, including Suven Life Sciences Limited and Aditum Life Sciences Private Limited. Formerly with 6 companies, such as Envirozyme Biotech Private Limited and Valetude Primus Healthcare Private Limited. Engaged in General Business, Technology and more. The 2 current companies with reported revenue have a combined latest revenue of ₹39.69 Cr; the largest is Dr.Reddy's Institute Of Life Sciences at ₹22.14 Cr (FY 2025).
Seyed Ehtesham Hasnain is associated with 5 companies as Director, including Dr.Reddy's Institute Of Life Sciences (₹22.14 Cr), Suven Life Sciences Limited (₹17.55 Cr), Ignovision Solutions Private Limited.
Seyed Ehtesham Hasnain has expertise in General Business, Technology and other sectors.
Seyed Ehtesham Hasnain has 20 years in corporate governance.
By reported revenue, the largest current company of Seyed Ehtesham Hasnain is Dr.Reddy's Institute Of Life Sciences, with revenue of ₹22.14 Cr (FY 2025).
The 2 current companies of Seyed Ehtesham Hasnain that report revenue have a combined latest revenue of ₹39.69 Cr.
Seyed Ehtesham Hasnain currently holds positions at 5 companies: Dr.Reddy's Institute Of Life Sciences (₹22.14 Cr), Suven Life Sciences Limited (₹17.55 Cr), Ignovision Solutions Private Limited, Aditum Life Sciences Private Limited, Sidsam Profeza Technologies India Private Limited.